Ocular Therapeutix enters quiet period for SOL-1 Phase 3 trial; data on track Q1 2026

OCULAR THERAPEUTIX, INC

Quiet period for SOL-1 Phase 3 trial of AXPAXLI (wet AMD) begins December 20, 2025.
Next investor communication expected early February 2026 with Q4/FY2025 results.
SOL-1 data remain on track for release in the first quarter of 2026.
No financial results or clinical data provided; no exhibits attached.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.